LON:SENS Sensyne Health (SENS) Share Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free SENS Stock Alerts GBX 0.35 -0.18 (-33.33%) (As of 06/17/2022) Add Compare Share Share Today's Range 0.16▼ 0.6050-Day Range 0.35▼ 0.3552-Week Range 0.16▼ 155Volume4.45 million shsAverage Volume3.45 million shsMarket Capitalization£582,624.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sensyne Health alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Sensyne Health Stock (LON:SENS)Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.Read More SENS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SENS Stock News HeadlinesMay 10, 2024 | americanbankingnews.comSensyne Health (LON:SENS) Shares Down 33.3% March 9, 2024 | forbes.comBest Collagen Powders Of 2024, According To ExpertsMay 11, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...December 8, 2023 | bbc.comNHS data sale 'an invasion of privacy', campaigners sayAugust 3, 2023 | investopedia.comAre Health Insurance Premiums Tax-Deductible?June 8, 2023 | forbes.comBMI Calculator: Check Your Body Mass IndexMay 27, 2023 | forbes.comFind The Right Health Insurance For YouApril 24, 2023 | marketwatch.com2023, The Health Self-monitoring Market is Expected to Witness a Substantial Rise in RevenueMay 11, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 5, 2023 | marketwatch.comHealth Self-monitoring Market Size 2023 With Strategic Choice-Making Process, Identification of Main CorporationsMarch 15, 2023 | marketwatch.comHealth Self-monitoring Market Forecast 2023 To 2029 Size, Global Predictive AnalyticsMarch 13, 2023 | marketwatch.comHealth Self-monitoring Market 2023 Future Size And Growth of a Market By 2029February 10, 2023 | marketwatch.comGlobal Health Self-monitoring Market 2023-A Detailed Analysis till 2029December 23, 2022 | thetimes.co.ukIn the year business leaders lost it, the winner isDecember 13, 2022 | msn.comChief of reborn Sensyne Health secures funding for growth planOctober 15, 2022 | marketwatch.comArtificial Intelligence in Diabetes Management Market 2022 : Global Industry Overview, Sales Revenue, Demand and Forecast by 2029 | 109 Report PagesSeptember 27, 2022 | marketwatch.comArtificial Intelligence in Diabetes Management Market to show impressive growth of 35.56% CAGR during the period 2022-2027 | 126 Report PagesAugust 17, 2022 | msn.comUK hospitals lose millions after AI startup valuation collapsesJuly 9, 2022 | msn.comWhy Oxford biotech needs more than a shot in the arm to surviveJuly 6, 2022 | msn.comHealth trusts swapped patient data for shares in an AI firm. They may have lost millionsMay 21, 2022 | msn.comParmy Olson: Medical care increasingly depends on health tech AI. That may not be good for you.May 11, 2022 | washingtonpost.comToo Much AI May Not Be Good for Your Health or the NHSApril 19, 2022 | thetimes.co.ukSnow takes over as Sensyne ditches saleApril 19, 2022 | lse.co.ukAIM WINNERS & LOSERS: Cake Box trading strong; Sensyne falls furtherApril 19, 2022 | lse.co.ukSensyne Health shares plummet as AIM delisting proposedApril 19, 2022 | marketwatch.comSensyne Health Ends Sale Process, to Delist From AIMApril 19, 2022 | proactiveinvestors.comSensyne Health ends sale process as refinancing plans are fleshed outSee More Headlines Receive SENS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensyne Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorComputer and Technology Industry Health Information Services Sub-IndustryN/A Current SymbolLON:SENS CUSIPN/A CIKN/A Webwww.sensynehealth.com Phone44 3300 581845FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio5.83 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio6.02 Current Ratio2.26 Quick Ratio2.26 Sales & Book Value Annual Sales£7.81 million Price / Sales0.07 Cash FlowGBX 4.90 per share Price / Cash Flow0.07 Book ValueGBX 20.30 per share Price / Book0.02Miscellaneous Outstanding Shares166,464,000Free FloatN/AMarket Cap£582,624.00 OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key CompetitorsDefenxLON:DFXTechFinancialsLON:TECHMaistroLON:MAISi-nexus GlobalLON:INXCatenae InnovationLON:CTEAView All Competitors SENS Stock Analysis - Frequently Asked Questions How have SENS shares performed in 2024? Sensyne Health's stock was trading at GBX 0.35 on January 1st, 2024. Since then, SENS shares have increased by 0.0% and is now trading at GBX 0.35. View the best growth stocks for 2024 here. What other stocks do shareholders of Sensyne Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sensyne Health investors own include Fresenius Medical Care (FME), Green Plains Partners (GPP), Hershey (HSY), Gilead Sciences (GILD), Griffon (GFF), Emerald (EEX), DHX Media (DHXM), Ctrip.Com International (CTRP), Corus Entertainment (CJR) and Citizens Financial Group (CFG). How do I buy shares of Sensyne Health? Shares of SENS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SENS) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensyne Health PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.